NeoGenomics (NEO) Q2 2026: NGS Revenue Jumps 26% as High-Value Testing Drives Margin Expansion
NeoGenomics’ high-value NGS testing mix powered both top-line growth and margin expansion, offsetting non-clinical weakness. With durable momentum in clinical and new product launches, management raised guidance and sharpened its focus on operational leverage and commercial execution. Investors should watch for further reimbursement wins and continued mix shift as key catalysts for the next phase of profitable growth.
Summary
- NGS Mix Shift Accelerates: High-value testing and new product launches are fueling sustainable growth and margin gains.
- Operational Discipline Deepens: Cost controls and Lab of the Future initiatives drive leverage, even as commercial investment rises.
- Guidance Raised on Clinical Strength: Management signals confidence in durable top-line and margin expansion through 2027.
Business Overview
NeoGenomics provides oncology-focused diagnostic testing, specializing in hematology and solid tumor molecular diagnostics. The company generates revenue primarily from its clinical testing (95% of revenue), serving pathologists and oncologists with next-generation sequencing (NGS), immunohistochemistry (IHC), and other modalities. A smaller non-clinical segment (5% of revenue) includes pharma services and oncology data solutions (ODS). NeoGenomics aims to capture share in therapy selection and minimal residual disease (MRD) markets through new product launches and reimbursement expansion.
Performance Analysis
NeoGenomics delivered 11% total revenue growth, driven by a 14% increase in clinical revenue and a notable 26% jump in NGS revenue. The growth in NGS, which now represents a third of clinical revenue, was propelled by both a 14% volume increase and a 12% rise in average unit price (AUP), reflecting a deliberate shift toward higher-value, larger-panel tests. This mix shift, alongside improvements from the Lab of the Future initiative (automation, digital pathology, and platform upgrades), led to a 260 basis point expansion in adjusted gross margin.
While the clinical business outperformed expectations, the non-clinical segment remained a drag, with pharma revenue down 26% year-over-year, only partially offset by 17% growth in ODS. Management emphasized that pharma is not core but remains a strategic enabler for pipeline validation and early market insight. Operating expenses declined 3% year-over-year (adjusted), as sales and R&D investment was offset by disciplined G&A reductions. Adjusted EBITDA rose 36% as margin and cost discipline translated into stronger cash flow.
- NGS Outpaces Market: Large-panel NGS and new product launches are driving sustained double-digit growth and margin benefit.
- Clinical-Nonclinical Divergence: Pharma segment underperformance is being actively managed, with full-year expectations reset and focus on 2027 recovery.
- Lab of the Future Yields Results: Automation, digital workflow, and platform upgrades are delivering measurable efficiency and cost leverage.
NeoGenomics’ financial health improved further with successful refinancing and share repurchases, extending debt maturities and maintaining a strong cash position. The company’s ability to consistently deliver on its clinical growth thesis, while containing costs, underpins the confidence in raised guidance and continued margin expansion targets.
Executive Commentary
"Our entry into these markets is driving growth across our entire NGS business, while providing halo effects to the rest of our portfolio. They're also helping to drive increases in our gross margin."
Tony Zook, Chief Executive Officer
"Gross margin expansion remains a key focus area for us, and we are pleased to see that our efforts have started to yield results on this metric."
Abhishek Jain, Chief Financial Officer
Strategic Positioning
1. NGS and High-Value Test Mix
NeoGenomics’ deliberate pivot toward high-complexity NGS panels and new solid tumor offerings is transforming its revenue base. With NGS now a third of clinical revenue and large panels growing over 20%, the company is capturing a greater share of the most profitable testing segments. This mix shift is both expanding margins and creating a durable growth engine, as legacy targeted panels convert to more comprehensive genomic profiling.
2. Product Innovation and Pipeline
Recent launches such as Pantracer Family and RadarST, targeting therapy selection and MRD, address a $33 billion market opportunity. Early commercial traction is promising, with RadarST’s reimbursement pipeline (three indications pending) set to unlock further share. The next-generation whole genome MRD assay, expected to generate data in 2027, positions NeoGenomics for leadership in emerging oncology diagnostics.
3. Commercial Execution and Channel Strength
Reorganization of the commercial team into oncology and pathology ecosystems sharpens focus and accountability. The company’s community-centric approach, Epic EHR integration, and high-touch workflow support are cited as differentiators that drive customer loyalty and net promoter scores in the high 70s. Expansion of the salesforce and targeted investments are aligned with new product launches and reimbursement milestones.
4. Operational Leverage and Cost Discipline
The Lab of the Future program—spanning digital pathology, AI-driven automation, and lab footprint optimization— is central to margin expansion. Closure of low-margin labs, platform transitions (NovaSeq X), and procurement efficiencies are delivering tangible cost savings. G&A leverage is a stated priority, with management targeting sub-30% of revenue by 2027.
5. Pharma and ODS: Strategic but Non-Core
Pharma services and ODS remain a small but strategically relevant segment, providing R&D insight and early access for pipeline validation. While not core to the growth thesis, management is committed to stabilizing and returning this segment to growth in 2027, leveraging improved bookings and operational changes.
Key Considerations
The quarter underscored NeoGenomics’ ability to execute on its high-value clinical growth strategy, while proactively managing cost and operational complexity. The following considerations frame the company’s evolving strategic context:
- Durability of NGS Growth: Management sees a multi-year runway for NGS mix shift, with legacy targeted panels still transitioning to large-panel and liquid biopsy solutions.
- Reimbursement as a Key Catalyst: Additional RadarST indications and private payer wins are critical to unlocking further MRD market share and revenue pull-through.
- Volume vs. AUP Dynamics: AUP-led growth is expected to continue through 2026, with volume growth reaccelerating as low-value contracts fully roll off and new products scale.
- Operational Efficiency: Lab of the Future initiatives and G&A discipline are driving sustainable margin expansion, allowing reinvestment in commercial and R&D priorities.
- Non-Clinical Segment Volatility: Pharma remains a small, non-core contributor, but bookings improvement and execution on backlog are necessary for 2027 stabilization.
Risks
Reimbursement timing and competitive intensity remain the most material risks, particularly in MRD and NGS where payer policy and adoption curves can shift rapidly. The company faces ongoing cost pressure from trade and labor, and must continue to deliver operational leverage as it scales. Pharma and ODS volatility, while not core, could distract management attention if underperformance persists. Regulatory changes around prior authorization and CMS policy, though not expected to be material in 2027, warrant monitoring.
Forward Outlook
For Q3 2026, NeoGenomics guided to:
- ~10% revenue growth (vs. prior 9–10% range)
- Continued adjusted EBITDA growth in the low 30% range
For full-year 2026, management raised guidance:
- Revenue: $802–806 million (from $797–803 million)
- NGS revenue growth: mid-20% (from low-20%)
- Gross margin: 100–150 basis points expansion
- Adjusted EBITDA: $56–58 million (over 30% YoY growth at midpoint)
Management highlighted several factors that underpin the outlook:
- Durable NGS momentum and mix shift to high-value tests
- Ongoing margin gains from Lab of the Future and cost discipline
- Pharma headwinds expected to persist but bookings improving
- Reimbursement wins and commercial expansion as key second-half catalysts
Takeaways
NeoGenomics is executing a high-value clinical growth strategy while driving sustainable margin expansion and cost leverage.
- NGS and High-Value Test Mix: The shift to large-panel and liquid biopsy NGS is both expanding margins and fueling top-line growth, underpinning the durability of the company’s model.
- Operational and Commercial Execution: Lab of the Future programs and commercial team reorganization are delivering measurable results, supporting reinvestment and future scalability.
- Key Watchpoints: Investors should monitor reimbursement milestones, volume-AUP mix dynamics, and the ability to stabilize non-clinical revenue as critical drivers for the next phase of growth.
Conclusion
NeoGenomics’ Q2 2026 results signal a business advancing on multiple strategic fronts, with high-value testing, operational leverage, and disciplined execution supporting both revenue and margin expansion. The raised guidance and clear focus on clinical core strengths position the company for continued durable growth, though reimbursement and non-clinical stabilization remain key watchpoints.
Industry Read-Through
The continued shift toward high-value NGS and MRD testing reflects broader trends in oncology diagnostics, with margin and revenue growth increasingly tied to mix optimization and workflow integration. NeoGenomics’ success with automation, digital pathology, and EHR integration highlights the operational arms race among diagnostics providers. The company’s approach to commercial segmentation and payer engagement may serve as a template for others seeking to scale in complex, reimbursement-driven markets. Watch for further consolidation and investment in lab automation and high-complexity testing as reimbursement and competitive forces intensify across the sector.